C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
Perioperative Chemotherapy in Muscle-Invasive Bladder Cancer to Enhance Survival and/or as a Strategy for Bladder Preservation
TL;DR: The urologic oncology community should actively support recruitment to ongoing adjuvant chemotherapy trials in order to answer the question of whether all patients should be treated with chemotherapy.
Journal ArticleDOI
New treatment approaches in metastatic renal cell carcinoma.
Andrea Mancuso,Cora N. Sternberg +1 more
TL;DR: In renal cell carcinoma, there is a strong rationale for targeting multiple pathways and particularly angiogenesis, and vascular endothelial growth factor- and platelet-derived growth factor receptor-inhibiting drugs have been rapidly approved in the second-line setting and will soon be used as first-line therapy.
Journal ArticleDOI
Phase II trial of didemnin B in patients with advanced renal cell carcinoma
TL;DR: Didemnin B is not recommended in the treatment of renal cell carcinoma and an allergic reaction was noted in four patients including one patient with anaphylaxis.
Journal Article
M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) and bladder preservation.
Howard I. Scher,H Herr,Cora N. Sternberg,William R. Fair,George J. Bosl,Michael J. Morse,Pramod C. Sogani,Robin C. Watson,D Darshaw,Victor E. Reuter +9 more
Journal ArticleDOI
Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial.
Cora N. Sternberg,Johann S. de Bono,Kim N. Chi,Karim Fizazi,Peter F.A. Mulders,Mohammad Hirmand,David Forer,Howard I. Scher +7 more
TL;DR: Improved outcomes with ENZA treatment were observed in both elderly and younger pts, with similar safety profiles in each age group, and safety and tolerability findings were comparable between the two age groups.